MBAI (MBAI) Stock Price & Analysis
MBAI (MBAI) fell 5.98% to USD 1.1 as of July 25, 2026 at 04:24 UTC, according to Nexqual real-time market data.
MBAI last closed at USD 1.17; the session ranged USD 1.1–1.19 on volume of 15,499 shares. Market capitalization is $8.50M, with a 52-week range of USD 0.59–3.92 (NCM). Source: Nexqual, July 25, 2026 at 04:24 UTC.
Key Statistics (as of July 25, 2026 at 04:24 UTC)
| Price | USD 1.1 |
|---|---|
| Change | ▼ 5.98% (down) |
| Previous Close | USD 1.17 |
| Open | USD 1.19 |
| Day Range | USD 1.1 – 1.19 |
| 52-Week Range | USD 0.59 – 3.92 |
| Volume | 15,499 shares |
| Market Cap | $8.50M |
| Exchange | NCM |
Technical Analysis (MBAI)
Nexqual's technical model rates MBAI "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:24 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.96 (neutral) |
| vs SMA50 | Below (USD 1.39) |
| MACD | -0.08 (negative) |
Analyst Ratings (MBAI)
Wall Street analysts rate MBAI "None", per Nexqual as of July 25, 2026 at 04:24 UTC.
| Consensus Rating | None |
|---|
Earnings (MBAI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -0.43 vs est -0.17 ▼ miss |
| 2023-06-30 | USD -0.94 vs est -0.53 ▼ miss |
| 2023-03-31 | USD -0.76 vs est -0.74 ▼ miss |
| 2022-12-31 | USD -0.64 vs est -0.98 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Financials & Fundamentals (MBAI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | +416.71% |
| Debt / Equity | 0.47 |
| Current Ratio | 0.05 |
| Total Cash | $219,000 |
| Total Debt | $16,000 |
| Free Cash Flow | $846,875 |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Financial Health Score (MBAI)
Nexqual rates MBAI's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:24 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $219K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$46K |
| Efficiency | Strong — ROE 417%, ROA -37.7% |
Ownership (MBAI)
| Insider Ownership | +37.48% |
|---|---|
| Institutional Ownership | +0.46% |
| Shares Outstanding | 7.73M |
| Float | 5.61M |
| Short % of Float | +1.51% |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Leadership (MBAI)
MBAI is led by David Lontini (age 44), Interim CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 04:24 UTC.
| Interim CEO & Chairman of the Board | David Lontini (age 44) |
|---|---|
| Chief Financial Officer | Alan Lewis (age 50) |
Major Backers & Investors (MBAI)
Notable institutional backers of MBAI include UBS Group AG, according to Nexqual as of July 25, 2026 at 04:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 0.39% |
Source: Nexqual, July 25, 2026 at 04:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JAGX | Jaguar Health, Inc. | USD 0.96 | ▼ 27.59% |
| FRSX | Foresight Autonomous Holdings L | USD 1.35 | ▼ 5.45% |
| TTOO | T2 Biosystems, Inc. | USD 0 | ▼ 77.78% |
| INUV | Inuvo, Inc. | USD 0.97 | ▼ 4.9% |
| SENS | Senseonics Holdings, Inc. | USD 4.86 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:24 UTC. This page is informational and not investment advice.